Cutaneous lupus erythematosus: Update of therapeutic options

Kuhn, Annegret; Ruland, Vincent; Bonsmann, Gisela

doi:10.1016/j.jaad.2010.06.018

Cited by 175 publications

(141 citation statements)

References 93 publications

(100 reference statements)

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…Ocular retinopathy is the most severe and frequent side effect of CQ and HCQ, requiring regular ophthalmological examinations to detect precocious and reversible abnormalities [1,65,78,79,80]. Although it is difficult to extrapolate these results in view of the retrospective nature of this study, the sensitivity to AM skin tests seems quite poor in detecting CADR.…”

Section: Discussionmentioning

confidence: 93%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

Background: Currently used antimalarial drugs (AM) are hydroxychloroquine and chloroquine, which are prescribed for many autoimmune disorders. The value of skin tests on cutaneous adverse drug reactions (CADR) with AM remains unknown. Objective: The main objective of this retrospective study is to know whether skin tests for AM are useful and how to manage the recovery of AM therapy in these patients. Methods: All patients referred for suspected CADR secondary to AM between 2001 and 2014 in eight French dermatology centers were retrospectively reviewed. Results: We report herein a retrospective series of 20 patients with CADR and AM involvement. Skin tests, performed in 14/20 patients, were negative in all cases. Six patients had an oral provocation test with recurrence of CADR in 1 case. Conclusion: We encourage dermatologists to perform oral provocation tests in nonsevere CADR in order to allow AM rechallenge at progressive doses.

show abstract

Section: Discussionmentioning

confidence: 93%

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Children in tropical countries may have some difficulties of sun avoidance; thus, parents as well as school teachers are encouraged to be vigilant about UV protection. Lack of sun exposure in affected individuals can sometimes result in low vitamin D levels; if so, vitamin D3 and calcium supplements should be considered [74]. …”

Section: Reviewmentioning

confidence: 99%

Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature

et al. 2015

View full text Add to dashboard Cite

Patients diagnosed with juvenile-onset systemic lupus erythematosus (JSLE) often have skin and oral lesions as part of their presentation. These mucocutaneous lesions, as defined by the American College of Rheumatology (ACR) in 1997, include malar rash, discoid rash, photosensitivity and oral ulcers. It is therefore essential to recognize mucocutaneous lesions to accurately diagnose JSLE. The mucocutaneous lesions can be divided into those with classical histological features (LE specific) and those strongly associated with and forming part of the diagnostic spectrum, but without the classical histological changes of lupus (LE nonspecific). A malar rash is the most commonly associated LE specific dermatological presentation. This skin manifestation is an acute form and also correlates with disease activity. Subacute (polycyclic or papulosquamous lesions) and chronic (discoid lesions) forms, whilst showing classical histological changes supportive of lupus, are less commonly associated with systemic lupus and do not correlate with disease activity. The most commonly associated skin lesions without classical lupus changes are cutaneous vasculitis, oral ulcers and diffuse non-scarring alopecia. These signs frequently relate to disease activity. An understanding of cutaneous signs and symptoms of lupus in children is important to avoid delay in diagnosis. They will often improve as lupus is adequately controlled and their reappearance is often the first indicator of a disease flare.

show abstract

“…Antimalarials like chloroquine (CHL) or hydroxychloroquine (HCHL) are first-line systemic agents for the treatment of CLE [2,3]. In chloroquine-resistant CLE patients, treatment with immunosuppressants and combinations with immunomodulators (e.g.…”

Section: Introductionmentioning

confidence: 99%

Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature

2015

View full text Add to dashboard Cite

Background: A variety of therapeutic options have been reported for cutaneous lupus erythematosus (CLE); one of these is dapsone. However, no high priority has been given to this drug. Objective: To determine whether dapsone is an effective and safe treatment alternative in patients with LE. Methods: We reviewed the literature and analyzed retrospectively 34 CLE patients who were treated with dapsone as monotherapy or combined with antimalarials. We assessed the course of the disease under treatment, response, concomitant treatment and side effects. Results: Six patients went into remission, 14 patients improved, and in 6 patients disease remained constant during the observation period. Dapsone was discontinued in 9 patients: in 4 due to reversible side effects and in 5 patients due to poor efficacy. Conclusion: Our data confirm that dapsone with/without antimalarials is effective in more than 50% of patients with CLE and could be used as second-line therapy for CLE.

show abstract

Cutaneous lupus erythematosus: Update of therapeutic options

Cited by 175 publications

References 93 publications

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests

Mucocutaneous manifestations in juvenile-onset systemic lupus erythematosus: a review of literature

Dapsone as Second-Line Treatment for Cutaneous Lupus Erythematosus? A Retrospective Analysis of 34 Patients and a Review of the Literature

Contact Info

Product

Resources

About